Lexicon Pharmaceuticals (NASDAQ:LXRX) Given Buy Rating at HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 486.51% from the stock’s previous close.

Several other equities analysts also recently weighed in on the company. StockNews.com raised Lexicon Pharmaceuticals to a “sell” rating in a research report on Tuesday, July 9th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, April 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, May 3rd. Finally, SVB Leerink started coverage on Lexicon Pharmaceuticals in a research report on Tuesday, April 30th. They issued an “outperform” rating and a $5.00 target price for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $7.50.

Lexicon Pharmaceuticals Trading Up 7.2 %

LXRX traded up $0.12 on Tuesday, hitting $1.71. The company had a trading volume of 1,753,137 shares, compared to its average volume of 3,631,420. The firm has a market cap of $419.83 million, a P/E ratio of -2.05 and a beta of 1.35. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.73. The company’s fifty day moving average price is $1.86 and its 200 day moving average price is $2.02. The company has a current ratio of 15.58, a quick ratio of 15.56 and a debt-to-equity ratio of 0.35.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. The firm had revenue of $1.65 million for the quarter, compared to analyst estimates of $2.74 million. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 115.40%. During the same period in the previous year, the firm earned ($0.22) EPS. As a group, equities analysts expect that Lexicon Pharmaceuticals will post -0.7 earnings per share for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in LXRX. Victory Capital Management Inc. lifted its stake in Lexicon Pharmaceuticals by 22.0% during the fourth quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 5,813 shares during the last quarter. Principal Securities Inc. purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter worth approximately $33,000. RPO LLC purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter worth approximately $49,000. Cantor Fitzgerald L. P. purchased a new stake in Lexicon Pharmaceuticals during the fourth quarter worth approximately $25,000. Finally, BVF Inc. IL lifted its stake in Lexicon Pharmaceuticals by 22.2% during the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock worth $37,387,000 after purchasing an additional 4,440,300 shares during the last quarter. Hedge funds and other institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.